Amgen Reports Phase 3 extension Data for Ivosidenib in Mucopolysaccharidosis

Amgen today announced Phase 3 extension results for Ivosidenib in patients with Mucopolysaccharidosis. The study demonstrated that Ivosidenib reduces disease progression risk by over 40% compared to standard of care or placebo. These results provide important insights into the treatment of Mucopolysaccharidosis and support the continued development of Ivosidenib in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results. The safety profile of Ivosidenib was consistent with previous observations, with no new safety signals identified.